Skip to main content
. Author manuscript; available in PMC: 2021 Jun 14.
Published in final edited form as: Semin Nucl Med. 2020 Jun 28;50(6):518–531. doi: 10.1053/j.semnuclmed.2020.06.001

Figure 3.

Figure 3

Representative case demonstrating a new proposed immune-related PERCIST classifications taking into account appearance of new FDG avid lesions as not progressive metastatic disease. A 66-year-old male classified as progressive metastatic disease by standard PERCIST criteria due to the appearance of a new lesion, but stable metastatic disease by immune-related imPERCIST5. Maximum-intensity-projection (MIP) images at baseline (A) and follow-up (B). Target lesions for imPERCIST5 are indicated by red arrows and the target lesion for PERCIST1 is indicated by red arrowhead. Comparison of axial images of the chest at baseline (C) and follow-up (D) show the development of a new hypermetabolic left hilar lymph node (white arrow), which was included in the target lesions for imPERCIST5. (This research was originally published in JNM. Ito K, et al. J Nucl Med. 2019;60(3):335–41.)43